Exicure Management

Management Kriterienprüfungen 0/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Paul Kang

Geschäftsführender

n/a

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	1.3yrs
Eigentum des Geschäftsführers	n/a
Durchschnittliche Amtszeit des Managements	1.3yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	1.3yrs

Jüngste Management Updates

Recent updates

Little Excitement Around Exicure, Inc.'s (NASDAQ:XCUR) Revenues As Shares Take 25% Pounding

Aug 29

Exicure to get $5.4M equity financing, reduce workforce & end R&D, preclinical activities

Sep 26

Exicure Q2 GAAP loss per share narrows, revenue up

Aug 15

Exicure regains compliance with Nasdaq's minimum bid price requirement

Jul 20

Exicure slides 31% as it implements reverse-stock-split to get back Nasdaq compliance

Jun 29

Does Exicure (NASDAQ:XCUR) Have A Healthy Balance Sheet?

Aug 25

Does Exicure (NASDAQ:XCUR) Have A Healthy Balance Sheet?

Mar 10

Geschäftsführer

Paul Kang (62 yo)

1.3yrs

Amtszeit

Mr. Paul Kang is Director of Exicure, Inc. from February 24, 2023 and serves as its Chief Executive Officer since August 21, 2023 and has been its President. He is associated with CBI USA Inc. Mr. Kang beg...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Paul Kang	CEO, President & Director	1.3yrs	keine Daten	keine Daten
Jiyoung Hwang	CFO, Secretary & Director	1.3yrs	keine Daten	keine Daten
Joshua Miller	Chief Accounting Officer	1.5yrs	keine Daten	0.011% $ 6.9k

1.3yrs

Durchschnittliche Betriebszugehörigkeit

48yo

Durchschnittliches Alter

Erfahrenes Management: XCURDas Führungsteam des Unternehmens gilt nicht als erfahren ( 1.3 Jahre durchschnittliche Betriebszugehörigkeit), was auf ein neues Team schließen lässt.

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Paul Kang	CEO, President & Director	1.8yrs	keine Daten	keine Daten
Jiyoung Hwang	CFO, Secretary & Director	1.8yrs	keine Daten	keine Daten
Michael Hodges	Member of Advisory Board	no data	keine Daten	keine Daten
Amy Paller	Member of Advisory Board	no data	keine Daten	keine Daten
Henry Paulson	Member of Advisory Board	4.9yrs	keine Daten	keine Daten
Hojoon Lee	Director	1.3yrs	keine Daten	keine Daten
Hyuk Ko	Independent Director	1.3yrs	keine Daten	keine Daten
Dongho Lee	Independent Director	1.3yrs	keine Daten	keine Daten
Minhee Eom	Independent Director	1.2yrs	keine Daten	keine Daten

1.3yrs

Durchschnittliche Betriebszugehörigkeit

56.5yo

Durchschnittliches Alter

Erfahrener Vorstand: XCURDie Vorstandsmitglieder gelten nicht als erfahren ( 1.3 Jahre durchschnittliche Amtszeit), was auf einen neuen Vorstand hindeutet.

Exicure Management

Management Kriterienprüfungen 0/4

Wichtige Informationen

Jüngste Management Updates

High number of new and inexperienced directors

Exicure, Inc. Appoints Anna Chukaeva as Senior Vice President, Head of Corporate Development and Bioinformatics

Exicure, Inc., Annual General Meeting, Jun 28, 2024

No independent directors

Exicure, Inc. Appoints Minhee Eom to the Board

Exicure, Inc. Announces Executive Changes

Recent updates

Exicure Request for Subsequent Extension to Nasdaq Hearings Panel Till December 17

New minor risk - Shareholder dilution

Nasdaq Hearings Panel Grants Exicure Extension for Continued Listing on The Nasdaq Capital Market, Compliance Required by November 14, 2024

Exicure Regains Compliance with the Minimum Bid Price Requirement Under Nasdaq Listing Rule 5550(a)(2)

Exicure Announces 1-for-5 Reverse Stock Split to Regain Compliance with Nasdaq’s Listing Rules

High number of new and inexperienced directors

Exicure, Inc. Appoints Anna Chukaeva as Senior Vice President, Head of Corporate Development and Bioinformatics

Exicure Receives Positive Listing Determination from Nasdaq

Exicure Receives Non-Compliance Letter Regarding Nasdaq Listing Rule 5550(b)(1)

Exicure, Inc., Annual General Meeting, Jun 28, 2024

Exicure, Inc. Receives Nasdaq Notice of A Delisting Determination

Exicure, Inc. announced delayed 10-Q filing

Exicure, Inc. announced delayed annual 10-K filing

New minor risk - Financial data availability

No independent directors

Exicure Receives Non-Compliance Notice From Nasdaq

Exicure Receives Nasdaq Delinquency Notice on Late Filing of its Form 10-Q

Exicure, Inc. announced delayed 10-Q filing

Exicure, Inc. Appoints Minhee Eom to the Board

Exicure Receives Non-Compliance Notice From Nasdaq

Little Excitement Around Exicure, Inc.'s (NASDAQ:XCUR) Revenues As Shares Take 25% Pounding

Exicure, Inc. Announces Executive Changes

Less than half of directors are independent

Exicure Notifies Nasdaq Regarding Continued to be Not in Compliance with Rule 5605(c)(2)(A)

Exicure Receives Nasdaq Delinquency Notice on Late Filing of its Form 10-Q

CBI USA Inc Sends a Letter to Exicure Inc

Exicure, Inc. announced delayed 10-Q filing

No independent directors

Exicure, Inc. Announces Resignation of Jeffrey L. Cleland from the Board of Directors, Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee

Exicure Receives Notice from Nasdaq Regarding No Longer in Compliance with Nasdaq's Independent Director and Audit Committee Requirements

Exicure, Inc. Announces Resignation of Jiyoung Hwang from the Board of Directors

Exicure, Inc. Announces Executive Changes

Exicure, Inc. Contemplates Bankruptcy

Exicure, Inc. announced that it expects to receive $5.44 million in funding from CBI Inc.

Exicure to get $5.4M equity financing, reduce workforce & end R&D, preclinical activities

Exicure Receives Noncompliance Notice from Nasdaq

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Exicure Q2 GAAP loss per share narrows, revenue up

Exicure Regains Compliance with Nasdaq Minimum Bid Price Requirement

Exicure regains compliance with Nasdaq's minimum bid price requirement

Exicure Announces Receipt of Nasdaq Notice of Non-Compliance

Exicure slides 31% as it implements reverse-stock-split to get back Nasdaq compliance

First quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Exicure, Inc. announced that it expects to receive $5.040289 million in funding from CBI USA, Inc, Abingworth LLP

High number of new and inexperienced directors

Exicure, Inc., Annual General Meeting, May 27, 2022

Exicure, Inc. Announces Executive, Board and Committee Changes

The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Exicure, Inc. Investors

Exicure Receives A Letter from the Staff Nasdaq Stock Market

Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Exicure, Inc

Price target decreased to US$6.75

Does Exicure (NASDAQ:XCUR) Have A Healthy Balance Sheet?

Consensus revenue estimates increase to US$12.9m

Second quarter 2021 earnings released: US$0.16 loss per share (vs US$0.049 loss in 2Q 2020)

Consensus revenue estimates increase to US$22.1m

Price target decreased to US$9.00

Exicure, Inc.(NasdaqCM:XCUR) dropped from Russell Microcap Value Index

Consensus revenue estimates fall to US$5.77m

Price target decreased to US$9.60

Exicure, Inc. Advances Clinical and Pre-Clinical Pipeline Designed to Bring Therapies to Patients with Unmet Medical Needs

First quarter 2021 earnings released: US$0.14 loss per share (vs US$0.013 profit in 1Q 2020)

Co-Founder & Director Chad Mirkin has left the company

Consensus revenue estimates increase to US$8.91m

Full year 2020 earnings released: US$0.28 loss per share (vs US$0.46 loss in FY 2019)

Earnings beat expectations, revenue disappoints

Exicure, Inc. Announces Spherical Nucleic Acid Technology Shows Promising Results in Phase 0 Trial in Patients with Glioblastoma

Exicure, Inc. Announces David R. Walt Did Not Stand for Re Election

Exicure Announces Appointments of Board of Directors

Does Exicure (NASDAQ:XCUR) Have A Healthy Balance Sheet?